Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05390424

Acronym

BUVARD76_27

Enrollment

500

Registered

2022-05-25

Start date

2022-12-02

Completion date

2027-01-01

Last updated

2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AIDS, Hepatitis B, Hepatitis C

Keywords

Dried Blood Spot

Brief summary

The aim of the study is to screen for hepatitis B, hepatitis C and AIDS viruses using a Dried Blood Spot in drug users

Interventions

DIAGNOSTIC_TESTBlood collection using Dried Blood Spot

Drug users will be screened for Hepatitis C, Hepatitis B and AIDS using Dried Blood Spot for blood collection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Former or active intravenous and/or nasal drug user * Person on opiate substitution therapy

Exclusion criteria

* Person with known active viral infection(s)

Design outcomes

Primary

Measure	Time frame
Number of person with an active hepatitis C infection	Day 1
Number of person with an active hepatitis B infection	Day 1
Number of person with an active AIDS infection	Day 1

Countries

France

Contacts

CONTACTGhassan RIACHI, MD

ghassan.riachi@chu-rouen.fr+3323288

CONTACTJulien BLOT

julien.blot@chu-rouen.fr+3323288

PRINCIPAL_INVESTIGATORGhassan RIACHI, MD

University Hospital, Rouen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026